Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
22 participants in 1 patient group
Loading...
Central trial contact
Anjali Avadhani, MD; Brad Johnson
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal